The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Open accessAbstract
Hepatitis B reactivation associated with immune suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus infection. The population at risk for HBV reactivation includes those who are either currently infected with HBV or have past exposure to HBV. Since curative and eradicative therapy for HBV is not currently available, there is a large reservoir of individuals at risk for HBV reactivation in the general population. HBV reactivation with its potential consequences is particularly a concern when these people are exposed to either cancer chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic conditions, malignancies, inflammatory bowel disease, dermatologic conditions, or solid organ or bone marrow transplantation. With the advent of newer and emerging forms of targeted biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. The aim of this review is to provide a comprehensive update on the current concepts, risk factors, molecular mechanisms, prevention and management of hepatitis B reactivation. In addition, we provide recommendations for future research in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examples of indirect hepatotoxicity include the immune‐mediated hepatitis (IMH) observed with immune checkpoint inhibitors (ICIs) and reactivation of HBV infection following rituximab infusions.7,8”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [7]
In the citing paper
“A third mechanism of hepatotoxicity is called indirect DILI, which arises when the biological action of the drug affects the host immune system, leading to a secondary form of liver injury.”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, B., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,115
Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,451
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
Self-citationMolecular biology of hepatitis B virus infection
Seeger, C., & Mason, W. S. (2015) · Virology · doi:10.1016/j.virol.2015.02.031 · Cited by 866
Reddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.039 · Cited by 861
Rehermann, B., Ferrari, C., Pasquinelli, C., & Chisari, F. V. (1996) · Nature Medicine · doi:10.1038/nm1096-1104 · Cited by 854
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1×
“It is known that liver is an active immune organ with active influx and efflux of immune cells.(69) These agents therefore may reduce the local immune”
BackgroundIMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
Guidotti, L. G., & Chisari, F. V. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100230 · Cited by 811
Yeo, W., Chan, P. K. S., Zhong, S., Ho, W. M., Steinberg, J. L., Tam, J. S., Hui, P., Leung, N. W. Y., Zee, B., & Johnson, P. J. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0 · Cited by 627
Reactivation of hepatitis B # †
Hoofnagle, J. H. (2009) · Hepatology · doi:10.1002/hep.22945 · Cited by 570
The Ins and Outs of Leukocyte Integrin Signaling
Abram, C. L., & Lowell, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132554 · Cited by 534
Perrillo, R. P., Gish, R., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.038 · Cited by 504
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function
Belloni, L., Pollicino, T., De Nicola, F., Guerrieri, F., Raffa, G., Fanciulli, M., Raimondo, G., & Levrero, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908365106 · Cited by 498
Pollicino, T., Belloni, L., Raffa, G., Pediconi, N., Squadrito, G., Raimondo, G., & Levrero, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.001 · Cited by 472
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
Rehermann, B. (2013) · Nature Medicine · doi:10.1038/nm.3251 · Cited by 468
Esteve, M., Saro, C., González-Huix, F., Suarez, F., Forné, M., & Viver, J. M. (2004) · Gut · doi:10.1136/gut.2004.040675 · Cited by 467
Loomba, R., Rowley, A., Wesley, R., Liang, T. J., Hoofnagle, J. H., Pucino, F., & Csako, G. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-7-200804010-00008 · Cited by 459
Self-citationStructural organization of the hepatitis B virus minichromosome
Bock, C. T., Schwinn, S., Locarnini, S., Fyfe, J., Manns, M. P., Trautwein, C., & Zentgraf, H. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4481 · Cited by 361
Evens, A. M., Jovanovic, B. D., Su, Y., Raisch, D. W., Ganger, D. R., Belknap, S. M., Dai, M.-S., Chiu, B.-C. C., Fintel, B., Cheng, Y., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq583 · Cited by 353
Calcineurin inhibitors: 40 years later, can’t live without
Azzi, J. R., Sayegh, M. H., & Mallat, S. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1390055 · Cited by 337
Huang, Y.-H., Hsiao, L.-T., Hong, Y.-C., Chiou, T.-J., Yu, Y.-B., Gau, J.-P., Liu, C.-Y., Yang, M.-H., Tzeng, C.-H., Lee, P.-C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5938 · Cited by 326
Present and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Self-citationYeo, W., Zee, B., Zhong, S., Chan, P. K. S., Wong, W.-L., Ho, W. M., Lam, K. C., & Johnson, P. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601699 · Cited by 312
Pérez-Alvarez, R., Díaz-Lagares, C., García-Hernández, F., Lopez-Roses, L., Brito-Zerón, P., Pérez-de-Lis, M., Retamozo, S., Bové, A., Bosch, X., Sanchez-Tapias, J.-M., et al. (2011) · Medicine · doi:10.1097/md.0b013e3182380a76 · Cited by 276
Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S. L., Haynes-Williams, V., Winters, M. A., Subramanya, G., Cooper, S. L., Pinto, P., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00074-2 · Cited by 269
Yeo, W., Chan, P. K. S., Ho, W. M., Zee, B. C.-Y., Lam, K. C., Lei, K. I. K., Chan, A. T. �., Mok, T. S. K., Lee, J. J., Leung, T. W. H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.161 · Cited by 259
Tropberger, P., Mercier, A., Robinson, M., Zhong, W., Ganem, D. E., & Holdorf, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518090112 · Cited by 246
Huang, H., Li, X., Zhu, J., Ye, S., Zhang, H., Wang, W., Wu, X., Peng, J., Xu, B., Lin, Y., et al. (2014) · JAMA · doi:10.1001/jama.2014.15704 · Cited by 232
Kinetics of Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis
Zhu, Y., Yamamoto, T., Cullen, J., Saputelli, J., Aldrich, C. E., Miller, D. S., Litwin, S., Furman, P. A., Jilbert, A. R., & Mason, W. S. (2001) · Journal of Virology · doi:10.1128/jvi.75.1.311-322.2001 · Cited by 226
Di Bisceglie, A. M., Lok, A. S., Martin, P., Terrault, N., Perrillo, R. P., & Hoofnagle, J. H. (2015) · Hepatology · doi:10.1002/hep.27609 · Cited by 225
Natural history of chronic hepatitis B in co-infected patients
Puoti, M., Torti, C., Bruno, R., Filice, G., & Carosi, G. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.015 · Cited by 224
Sung, J. J. Y., Wong, M.-L., Bowden, S., Liew, C.-T., Hui, A. Y., Wong, V. W. S., Leung, N. W. Y., Locarnini, S., & Chan, H. L. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.009 · Cited by 218
Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression
Löwenberg, M., Verhaar, A. P., van den Brink, G. R., & Hommes, D. W. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.02.001 · Cited by 189
Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Paul, S., Saxena, A., Terrin, N., Viveiros, K., Balk, E. M., & Wong, J. B. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1121 · Cited by 177
Lan, J., Chen, Y., Hsieh, T., Chen, Y., Hsieh, C.-W., Chen, D.-Y., & Yang, S. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.148783 · Cited by 173
The role of innate immunity in the immunopathology and treatment of HBV infection
Maini, M. K., & Gehring, A. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.028 · Cited by 164
Lee, Y. H., Bae, S., & Song, G. G. (2013) · PubMed · Cited by 155
Monte, A. D., Courjon, J., Anty, R., Cua, É., Naqvi, A., Mondain, V., Cottalorda, J., Ollier, L., & Giordanengo, V. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.02.026 · Cited by 131
Mozessohn, L., Chan, K., Feld, J. J., & Hicks, L. K. (2015) · Journal of Viral Hepatitis · doi:10.1111/jvh.12402 · Cited by 126
Kohrt, H. E. K., Ouyang, D. L., & Keeffe, E. B. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03081.x · Cited by 123
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells
Chüeh, A. C., Tse, J. W. T., Tögel, L., & Mariadason, J. M. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5863 · Cited by 109
Ikeda, K., Shiga, Y., Takahashi, A., Kai, T., Kimura, H., Takeyama, K., Noji, H., Ogawa, K., Nakamura, A., Ohira, H., et al. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/14639230500236818 · Cited by 92
Zhang, M., Zhu, G., Shi, K., Zheng, J.-N., Cheng, Z., Zou, Z., Huang, H., Chen, F., & Zheng, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8907 · Cited by 76
Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor
Lai, G.-M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i8.1318 · Cited by 72
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000449342 · Cited by 70
Crohn’s disease: A review of treatment options and current research
Bandzar, S., Gupta, S., & Platt, M. O. (2013) · Cellular Immunology · doi:10.1016/j.cellimm.2013.11.003 · Cited by 68
Ritchie, D., Piekarz, R., Blombery, P. A., Karai, L., Pittaluga, S., Jaffe, E. S., Raffeld, M. A., Janik, J. E., Prince, H. M., & Bates, S. E. (2009) · Haematologica · doi:10.3324/haematol.2009.008607 · Cited by 67
Kato, M., Atsumi, T., Kurita, T., Odani, T., Fujieda, Y., Otomo, K., Horita, T., Yasuda, S., & Koike, T. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110289 · Cited by 53
Kim, M. K., Ahn, J. H., Kim, S., Im, Y.-S., Lee, S. I., Ahn, S., Son, B. H., Gong, G., Kim, H.-H., & Kim, W. K. (2007) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2007.22.4.237 · Cited by 49
Ceccarelli, L. A., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., Ricciardi, A., Perno, C. F., Andreoni, M., & Sarrecchia, C. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.11.021 · Cited by 47
Koskinas, J. S., Tampaki, M., Doumba, P. P., & Rallis, E. A. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12120 · Cited by 47
Li, J., Huang, B., Li, Y., Zheng, D., Zhou, Z., & Liu, J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.941833 · Cited by 42
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy
Lakhani, S., Davidson, L., Priebat, D. A., et al. (2008) · Hepatology International · doi:10.1007/s12072-008-9099-5 · Cited by 37
Visram, A., Chan, K., McGee, P., Boro, J., Hicks, L. K., & Feld, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120749 · Cited by 37
Anti-CD20 antibody treatment of non-Hodgkin lymphomas
Engelhard, M. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.08.011 · Cited by 33
Ho, E. Y., Yau, T. C. C., Rousseau, F. S., Heathcote, E. J., & Lau, G. K. K. (2015) · Hepatology International · doi:10.1007/s12072-015-9612-6 · Cited by 20
Cited by
Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Metadata
- Authors
- Loomba, R., & Liang, T. J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 152
- Issue
- 6
- Pages
- 1297-1309
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2590941489
- Cited by
- 594
- References
- 63
- FWCI
- 38.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.